Celltrion Usa

Celltrion Usa company information, Employees & Contact Information

Explore related pages

Related company profiles:

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to biologics to improve care for U.S. patients. Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence, and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients.

Company Details

Employees
117
Founded
-
Address
1 Evertrust Plaza, Jersey City,new Jersey 07302,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Manager jobs.
HQ
Jersey City, New Jersey
Looking for a particular Celltrion Usa employee's phone or email?

Celltrion Usa Questions

News

Adalimumab Biosimilar Yuflyma Gets Approval for Additional Pediatric Indications - Optometry Advisor

Adalimumab Biosimilar Yuflyma Gets Approval for Additional Pediatric Indications Optometry Advisor

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo) - PR Newswire

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo) PR Newswire

Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept) - us.acrofan.com

Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept) us.acrofan.com

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients - PR Newswire

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients PR Newswire

Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States - The Manila Times

Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States The Manila Times

FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States - us.acrofan.com

FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States us.acrofan.com

STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States - Yahoo Finance

STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States Yahoo Finance

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) - Yahoo Finance

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) Yahoo Finance

Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program - PR Newswire

Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program PR Newswire

Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRA™ - PR Newswire

Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRA™ PR Newswire

U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR® - PR Newswire

U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR® PR Newswire

Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA® - PR Newswire

Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA® PR Newswire

Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab) - PR Newswire

Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab) PR Newswire

Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab) - PR Newswire

Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab) PR Newswire

Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost - PR Newswire

Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost PR Newswire

Celltrion USA Launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar, in the United States - Business Wire

Celltrion USA Launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar, in the United States Business Wire

Top Celltrion Usa Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant